Immune System News and Research

RSS

JDRF partners with Pfizer's CTI to support diabetes research

JDRF, the leading global organization funding type 1 diabetes research, announced today a partnership with Pfizer's Centers for Therapeutic Innovation to support the development and translation of promising diabetes research.

4 Nov 2013

Probiotics may help keep bad germs at bay

Microbes are everywhere - thousands of species are in your mouth, and thousands are in a glass of tap water. The ones in your mouth are mostly harmless - as long as you brush and floss so they don't form a biofilm that allows gum disease a path into the blood stream.

4 Nov 2013

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.

4 Nov 2013

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood.

4 Nov 2013

Research roundup: States struggling with Medicaid expansion "complex issues"

We conducted a secondary analysis of data (2005 to 2010) from the Medical Expenditure Panel Survey. ... Comparisons were made between 2 groups to reflect likely movements in insurance status after the Patient Protection and Affordable Care Act implementation: (1) the uninsured who will be Medicaid eligible afterward versus Medicaid insured, and (2) the uninsured who will be Medicaid ineligible afterward versus the privately insured. ...

4 Nov 2013

Research findings offer new therapeutic paradigm for periodontal disease

The red, swollen and painful gums and bone destruction of periodontal disease could be effectively treated by beckoning the right kind of immune system cells to the inflamed tissues, according to a new animal study conducted by researchers at the University of Pittsburgh.

4 Nov 2013

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Nov 2013

SRI to expand current preclinical molecular imaging capabilities with MILabs VECTor+ system

MILabs is pleased to announce that Sunnybrook Research Institute, the research arm of the Sunnybrook Health Sciences Centre, located in Toronto, Canada will install a MILabs VECTor+ system to expand their current preclinical molecular imaging capabilities.

4 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

Taking care of your gums by brushing could help hold heart disease at bay

Taking care of your gums by brushing, flossing, and regular dental visits could help hold heart disease at bay. Researchers at Columbia University's Mailman School of Public Health have shown for the first time that as gum health improves, progression of atherosclerosis slows to a clinically significant degree. Findings appear online in the Journal of the American Heart Association.

3 Nov 2013

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, at the 15th World Conference on Lung Cancer in Sydney, Australia (Abstract #2416).

31 Oct 2013

VG Life Sciences' peptide awarded US patent for HIV treatment

The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection.

31 Oct 2013

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

Making fat cells immortal might seem like a bad idea to most people, but for a team of University of Iowa scientists it was the ideal way to study how the interaction between bacteria and fat cells might contribute to diabetes.

31 Oct 2013

New finding could help lead to better treatments for eczema

For the millions of people suffering from the intensely red, horribly itchy skin condition known as eczema, the only thing more maddening than their disease is the lack of understanding of what causes it, or makes it flare up from time to time.

31 Oct 2013

Scientists unravel the major cause of protein citrullination in rheumatoid arthritis

Experiments by scientists at Johns Hopkins and in Boston have unraveled two biological mechanisms as the major cause of protein citrullination in rheumatoid arthritis. Protein citrullination is suspected of sparking the immune system and driving the cascade of events leading to the disease.

31 Oct 2013

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine.

31 Oct 2013

New insights into human cytomegalovirus may lead to development of therapeutic interventions

New insights into how human cytomegalovirus, the leading cause of birth defects associated with infection spreads from pregnant mother to fetus and from organ to organ in newborns provides translational researchers an exciting new avenue for investigation that may lead to the development of therapeutic interventions.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

UofL researcher enters into license and research collaboration agreement with Novartis

The University of Louisville today announced that researcher Dr. Suzanne Ildstad, representing Regenerex LLC, has entered into a license and research collaboration agreement with Novartis to provide access to stem cell technology that has the potential to help transplant patients avoid taking anti-rejection medicine for life and could serve as a platform for treatment of other diseases.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

Immune System News and Research

JDRF partners with Pfizer's CTI to support diabetes research

Probiotics may help keep bad germs at bay

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

Patients with mutation in gene encoding CX3CR1 at higher risk of candidiasis

Research roundup: States struggling with Medicaid expansion "complex issues"

Research findings offer new therapeutic paradigm for periodontal disease

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

SRI to expand current preclinical molecular imaging capabilities with MILabs VECTor+ system

Experimental drug effective in treating patients with non-small cell lung cancer

Taking care of your gums by brushing could help hold heart disease at bay

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

VG Life Sciences' peptide awarded US patent for HIV treatment

Interaction between fat cells and bacterial toxins can lead to chronic inflammation

New finding could help lead to better treatments for eczema

Scientists unravel the major cause of protein citrullination in rheumatoid arthritis

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

New insights into human cytomegalovirus may lead to development of therapeutic interventions

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

UofL researcher enters into license and research collaboration agreement with Novartis

Immune Design closes Series C financing totalling up to $49M

Immunology eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News